While many financial advisors will direct you to established public enterprises, investors seeking some “oomph” for their portfolio may want to target “unmatched” stocks with potential. Rather than walking along the beaten path, these lesser-known entities carry significantly higher risk. At the same time, if circumstances align just right, you could enjoy massive upside. To
0 Comments
Jen-Hsun Huang, CEO, Nvidia David Paul Morris | Bloomberg | Getty Images Check out the companies making headlines in the premarket. Nvidia — The chipmaker popped 7% after reporting another blowout quarter that topped Wall Street’s estimates. Nvidia also offered optimistic guidance, saying that sales will jump 170% during the current period as demand for
0 Comments
Barron’s published an article in mid-August that discussed how the best employers are the best stocks to buy. Jefferies Financial Group (NYSE:JEF) analysis found that the stocks of the companies on the annual Fortune list of top 100 workplaces had consistently outperformed their peers since 1998 when the list was started. “Analysts led by Aniket
0 Comments
Quantum computing, a field that leverages the principles of quantum physics, has been steadily gaining traction over the years. Among the companies vying for dominance in this nascent industry, IonQ (NASDAQ:IONQ) stands out with its unique approach to quantum computing. Despite the compelling story painted by the company, however, investors should tread carefully with IONQ
0 Comments
Nvidia headquarters in Santa Clara, California, June 5, 2023. Marlena Sloss | Bloomberg | Getty Images Check out the companies making headlines in extended trading. Splunk — Shares added 11% after an earnings beat. Splunk earned 71 cents per share, after adjustments, on $889 million in revenue. Analysts polled by FactSet had forecast Splunk would
0 Comments
Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper.  Traditionally, most biotech stock drug candidates fail. Indeed, according to Nature, “An estimated 86% of drug candidates developed between 2000 and 2015 did not meet their stated endpoints.” And the well-respected consulting firm McKinsey reported that “Today, to discover and develop a
0 Comments
Crypto stocks, like crypto overall, face a volatile environment that shifts quickly and is affected by domestic and global policy. Stablecoins have taken the spotlight currently. Many developed economies are regulating stablecoins but the United States looks unlikely to follow suit. Regulation of U.S. stablecoins threatens the U.S. dollar and its dominant position. It’s a
0 Comments